T1	Condition 16 29	heart failure
T2	Condition 41 62	diastolic dysfunction
T3	Negation 30 40	other than
R1	Has_negation Arg1:T2 Arg2:T3	
R2	AND Arg1:T1 Arg2:T2	
T4	Condition 72 98	restrictive cardiomyopathy
T5	Condition 102 129	infiltrative cardiomyopathy
*	OR T4 T5
T6	Scope 72 129	restrictive cardiomyopathy or infiltrative cardiomyopathy
T7	Scope 16 62	heart failure other than diastolic dysfunction
R3	Subsumes Arg1:T7 Arg2:T6	
T8	Person 131 136	Women
T9	Condition 145 153	pregnant
T10	Condition 157 164	nursing
*	OR T9 T10
T11	Condition 166 181	Liver cirrhosis
T12	Condition 184 208	Primary valvular disease
T13	Condition 210 233	Acute coronary syndrome
T14	Condition 235 247	Causes of PH
T15	Negation 248 258	other than
T16	Condition 267 280	heart failure
R4	Has_negation Arg1:T16 Arg2:T15	
R5	AND Arg1:T14 Arg2:T16	
T17	Condition 291 316	chronic thromboembolic PH
T18	Condition 318 337	sickle-cell disease
T19	Condition 342 353	sarcoidosis
*	OR T19 T18 T17
T20	Scope 291 353	chronic thromboembolic PH, sickle-cell disease, or sarcoidosis
R6	Has_scope Arg1:T16 Arg2:T20	
T21	Condition 362 373	bradycardia
T22	Qualifier 355 361	Severe
R7	Has_qualifier Arg1:T21 Arg2:T22	
T23	Qualifier 377 400	greater than 1st degree
T24	Condition 401 412	heart block
R8	Has_qualifier Arg1:T24 Arg2:T23	
*	OR T21 T24
T25	Condition 428 441	heart failure
T26	Qualifier 414 427	Decompensated
R9	Has_qualifier Arg1:T25 Arg2:T26	
T27	Drug 460 489	third generation beta-blocker
T28	Drug 491 500	nebivolol
T29	Drug 502 512	carvedilol
T30	Drug 517 526	labetalol
*	OR T30 T29 T28
T31	Scope 491 526	nebivolol, carvedilol, or labetalol
R10	Subsumes Arg1:T27 Arg2:T31	
T32	Multiplier 531 540	high dose
T33	Drug 544 561	any beta-blockers
T34	Multiplier 563 588	greater than 100 mg daily
T35	Drug 592 602	metoprolol
R11	Has_multiplier Arg1:T35 Arg2:T34	
R12	Has_multiplier Arg1:T33 Arg2:T32	
T36	Scope 563 602	greater than 100 mg daily of metoprolol
T37	Scope 531 561	high dose of any beta-blockers
R13	Subsumes Arg1:T37 Arg2:T36	
*	OR T37 T27
